<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03576183</url>
  </required_header>
  <id_info>
    <org_study_id>VLA1701-201</org_study_id>
    <nct_id>NCT03576183</nct_id>
  </id_info>
  <brief_title>Study Confirming A Human Challenge Model and Investigating The Safety Of VLA1701</brief_title>
  <official_title>Randomized Double-Blinded Pilot Study Confirming A Human Challenge Model Using LSN03-016011/A Expressing LT And CS17 And Investigating The Safety Of VLA1701 (An Investigational Oral Cholera And ETEC (Enterotoxigenic E Coli) (Vaccine)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valneva Austria GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Naval Medical Research Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Valneva Austria GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, double-blind, placebo-controlled, Phase II vaccination and challenge&#xD;
      study designed to confirm a human challenge model with E. coli strain LSN03-016011/A.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-center, double-blind, placebo-controlled, Phase II vaccination and challenge&#xD;
      study designed to confirm a human challenge model with E. coli strain LSN03-016011/A (LT+&#xD;
      (Labile toxin), ST- (Stable toxin), CS17), as well as collect expanded safety and&#xD;
      immunogenicity data.&#xD;
&#xD;
      The study will be carried out in two phases:&#xD;
&#xD;
      Vaccination phase: up to 34 subjects will be randomized 1:1 to receive 2 doses of either&#xD;
      VLA1701 or placebo orally. The doses will be given 7 days apart and subjects will be followed&#xD;
      as an outpatient for safety.&#xD;
&#xD;
      Challenge Phase: 30 Subjects, out of the 34 subjects, will be challenged.&#xD;
&#xD;
      After challenge, subjects will be monitored for diarrhea and other signs/symptoms of enteric&#xD;
      illness by daily medical checks, vital sign determinations, grading and weighing of all&#xD;
      stools.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 4, 2018</start_date>
  <completion_date type="Actual">November 30, 2018</completion_date>
  <primary_completion_date type="Actual">June 26, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Double (Participant, Investigator)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects With Moderate to Severe Diarrhea</measure>
    <time_frame>5 days after challenge</time_frame>
    <description>within 120 hours of challenge with ETEC strain LSN03-016011/A.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Severity Score After Challenge With ETEC Strain LSN03-016011/ A</measure>
    <time_frame>7 days after challenge</time_frame>
    <description>ETEC diarrhea disease severity score with a score ranging from 0 (no disease) to 8 (most severe disease) utilizing objective signs, subjective Symptoms and stool output.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Solicited Adverse Events</measure>
    <time_frame>7days after each vaccination</time_frame>
    <description>adverse events covered by the subjects memory card</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Any Adverse Events (AE)</measure>
    <time_frame>until Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Serious Adverse Events</measure>
    <time_frame>until Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Any IMP (Investigational Medicinal Product) Related Adverse Events</measure>
    <time_frame>up to Visit 4 (day of challenge, 23 days post first vaccination)</time_frame>
    <description>unsolicited events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With IMP-related Serious Adverse Events</measure>
    <time_frame>up to Visit 4 (day of challenge, 23 days post first vaccination)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Enterotoxigenic Escherichia Coli Infection</condition>
  <condition>Diarrhea</condition>
  <arm_group>
    <arm_group_label>VLA1701</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>VLA1701 is an investigational oral vaccine against LT-ETEC (Labile Toxin-Enterotoxigenic E coli)&#xD;
The vaccine is administered orally in 2 doses about 1 week apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The buffer component of VLA1701 will be used as Placebo.&#xD;
The vaccine is administered orally in 2 doses about 1 week apart.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VLA1701</intervention_name>
    <description>VLA1701 is an investigational oral vaccine against LT-ETEC (Labile Toxin-Enterotoxigenic E coli)</description>
    <arm_group_label>VLA1701</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>buffer component of VLA1701</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Challenge Strain</intervention_name>
    <description>LSN03-016011/A</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>VLA1701</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male and non-pregnant female subjects aged 18 to &lt;50 years;&#xD;
&#xD;
          2. BMI of 19.0 to 35.0 kg/m2&#xD;
&#xD;
          3. Willingness to participate after informed consent has been obtained from the subject&#xD;
             prior to any study related procedures.&#xD;
&#xD;
          4. Completion of a training session and demonstration of comprehension of the protocol&#xD;
             procedures and knowledge of ETEC-associated illness by passing a written examination.&#xD;
&#xD;
          5. If subject is of childbearing potential:&#xD;
&#xD;
               1. Negative pregnancy test at screening with understanding to not become pregnant&#xD;
                  within 28 days after challenge;&#xD;
&#xD;
               2. Subject has practiced an effective method of contraception during the 30 days&#xD;
                  before screening (Visit 0);&#xD;
&#xD;
               3. Subject agrees to employ adequate birth control measures for the duration of the&#xD;
                  study.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Participated in research involving investigational product within 30 days before&#xD;
             planned date of first vaccination or planned use through Day 44;&#xD;
&#xD;
          2. Any prior exposure to ETEC (including LSN03-016011/A) or cholera occupationally or&#xD;
             received LT (Or any mutant forms of LT (e.g., LTR192G, LTR192GL211A), ETEC, or cholera&#xD;
             vaccine);&#xD;
&#xD;
          3. Subjects with known abnormal stooling patterns (fewer than 3 per week or more than 3&#xD;
             per day);&#xD;
&#xD;
          4. Known allergies to any component of the vaccine;&#xD;
&#xD;
          5. Subjects with known allergies to more than 1 planned antibiotics:&#xD;
&#xD;
          6. History of diarrhea while traveling in a developing country within the last 3 years;&#xD;
&#xD;
          7. Subjects whose occupation involves handling of ETEC or cholera bacteria;&#xD;
&#xD;
          8. Women who are pregnant or breastfeeding;&#xD;
&#xD;
          9. Significant medical conditions including chronic, immunosuppressive, malignant, or&#xD;
             gastrointestinal diseases (e.g. History of Irritable Bowel Syndrome (as defined by the&#xD;
             Rome III criteria or medical diagnosis) or gastric ulcer disease) or enteric,&#xD;
             pulmonary, cardiac, liver or renal disease. Some medical conditions which are&#xD;
             adequately treated and stable may be acceptable in the study (e.g. hypertension);&#xD;
&#xD;
         10. Significant abnormalities in screening lab hematology or serum chemistries;&#xD;
&#xD;
         11. Use of any medication known to effect the immune system (e.g. systemic&#xD;
             corticosteroids) within 30 days of vaccination or planned use during active study&#xD;
             period (excluding inhaled steroids);&#xD;
&#xD;
         12. Evidence of confirmed infection with HIV, Hepatitis B or Hepatitis C;&#xD;
&#xD;
         13. Subjects with IgA (Immunoglobulin A) deficiency (serum IgA &lt; 7 mg/dl or limit of&#xD;
             detection of assay);&#xD;
&#xD;
         14. Regular use of antacids, antidiarrheal, loperamide, bismuth subsalicylate,&#xD;
             diphenoxylate or similar medication less than 2 weeks prior to enrolling in the study&#xD;
             and through the inpatient portion of the study;&#xD;
&#xD;
         15. Known or suspected alcohol abuse or illicit drug use within the last year, positive&#xD;
             urine toxicology for drugs of abuse;&#xD;
&#xD;
         16. Persons who are committed to an institution (by virtue of an order issued either by&#xD;
             the judicial or the administrative authorities);&#xD;
&#xD;
         17. Persons who are in a dependent relationship with the sponsor, an investigator or other&#xD;
             study team members, or the study center.&#xD;
&#xD;
         18. Any other criteria which, in the investigator's opinion, would compromise the ability&#xD;
             of the subject to participate in the study, the safety of the study, or the results of&#xD;
             the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Taucher, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Valneva Austria GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of International Health Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 15, 2018</study_first_submitted>
  <study_first_submitted_qc>June 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 3, 2018</study_first_posted>
  <results_first_submitted>June 29, 2020</results_first_submitted>
  <results_first_submitted_qc>March 29, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 23, 2021</results_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Escherichia coli Infections</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 30, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT03576183/Prot_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 16, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT03576183/SAP_003.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>VLA1701</title>
          <description>VLA1701 is an investigational oral vaccine against LT-ETEC (Labile Toxin-Enterotoxigenic E coli)&#xD;
The vaccine is administered orally in 2 doses about 1 week apart.&#xD;
VLA1701: VLA1701 is an investigational oral vaccine against LT-ETEC (Labile Toxin-Enterotoxigenic E coli)&#xD;
Challenge Strain: LSN03-016011/A</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>The buffer component of VLA1701 will be used as Placebo.&#xD;
The vaccine is administered orally in 2 doses about 1 week apart.&#xD;
Placebo: buffer component of VLA1701&#xD;
Challenge Strain: LSN03-016011/A</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Challenge Population = all subjects who received two doses of the vaccine and the challenge dose</population>
      <group_list>
        <group group_id="B1">
          <title>VLA1701</title>
          <description>VLA1701 is an investigational oral vaccine against LT-ETEC (Labile Toxin-Enterotoxigenic E coli)&#xD;
The vaccine is administered orally in 2 doses about 1 week apart.&#xD;
VLA1701: VLA1701 is an investigational oral vaccine against LT-ETEC (Labile Toxin-Enterotoxigenic E coli)&#xD;
Challenge Strain: LSN03-016011/A</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>The buffer component of VLA1701 will be used as Placebo.&#xD;
The vaccine is administered orally in 2 doses about 1 week apart.&#xD;
Placebo: buffer component of VLA1701&#xD;
Challenge Strain: LSN03-016011/A</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.2" spread="7.89"/>
                    <measurement group_id="B2" value="35.1" spread="9.09"/>
                    <measurement group_id="B3" value="35.1" spread="8.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian or Alaskan Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other: Multi-racial</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other: Latino / Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With Moderate to Severe Diarrhea</title>
        <description>within 120 hours of challenge with ETEC strain LSN03-016011/A.</description>
        <time_frame>5 days after challenge</time_frame>
        <population>Challenge Population = all subjects who received two doses of the vaccine and the challenge dose</population>
        <group_list>
          <group group_id="O1">
            <title>VLA1701</title>
            <description>VLA1701 is an investigational oral vaccine against LT-ETEC (Labile Toxin-Enterotoxigenic E coli)&#xD;
The vaccine is administered orally in 2 doses about 1 week apart.&#xD;
VLA1701: VLA1701 is an investigational oral vaccine against LT-ETEC (Labile Toxin-Enterotoxigenic E coli)&#xD;
Challenge Strain: LSN03-016011/A</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>The buffer component of VLA1701 will be used as Placebo.&#xD;
The vaccine is administered orally in 2 doses about 1 week apart.&#xD;
Placebo: buffer component of VLA1701&#xD;
Challenge Strain: LSN03-016011/A</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Moderate to Severe Diarrhea</title>
          <description>within 120 hours of challenge with ETEC strain LSN03-016011/A.</description>
          <population>Challenge Population = all subjects who received two doses of the vaccine and the challenge dose</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Severity Score After Challenge With ETEC Strain LSN03-016011/ A</title>
        <description>ETEC diarrhea disease severity score with a score ranging from 0 (no disease) to 8 (most severe disease) utilizing objective signs, subjective Symptoms and stool output.</description>
        <time_frame>7 days after challenge</time_frame>
        <population>Challenge Population = all subjects who received two doses of the vaccine and the challenge dose</population>
        <group_list>
          <group group_id="O1">
            <title>VLA1701</title>
            <description>VLA1701 is an investigational oral vaccine against LT-ETEC (Labile Toxin-Enterotoxigenic E coli)&#xD;
The vaccine is administered orally in 2 doses about 1 week apart.&#xD;
VLA1701: VLA1701 is an investigational oral vaccine against LT-ETEC (Labile Toxin-Enterotoxigenic E coli)&#xD;
Challenge Strain: LSN03-016011/A</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>The buffer component of VLA1701 will be used as Placebo.&#xD;
The vaccine is administered orally in 2 doses about 1 week apart.&#xD;
Placebo: buffer component of VLA1701&#xD;
Challenge Strain: LSN03-016011/A</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Severity Score After Challenge With ETEC Strain LSN03-016011/ A</title>
          <description>ETEC diarrhea disease severity score with a score ranging from 0 (no disease) to 8 (most severe disease) utilizing objective signs, subjective Symptoms and stool output.</description>
          <population>Challenge Population = all subjects who received two doses of the vaccine and the challenge dose</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="1.7"/>
                    <measurement group_id="O2" value="3.7" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Solicited Adverse Events</title>
        <description>adverse events covered by the subjects memory card</description>
        <time_frame>7days after each vaccination</time_frame>
        <population>Safety Population = all subjects who entered into the study and received at least one vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>VLA1701</title>
            <description>VLA1701 is an investigational oral vaccine against LT-ETEC (Labile Toxin-Enterotoxigenic E coli)&#xD;
The vaccine is administered orally in 2 doses about 1 week apart.&#xD;
VLA1701: VLA1701 is an investigational oral vaccine against LT-ETEC (Labile Toxin-Enterotoxigenic E coli)&#xD;
Challenge Strain: LSN03-016011/A</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>The buffer component of VLA1701 will be used as Placebo.&#xD;
The vaccine is administered orally in 2 doses about 1 week apart.&#xD;
Placebo: buffer component of VLA1701&#xD;
Challenge Strain: LSN03-016011/A</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Solicited Adverse Events</title>
          <description>adverse events covered by the subjects memory card</description>
          <population>Safety Population = all subjects who entered into the study and received at least one vaccination</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6" lower_limit="6.2" upper_limit="41.0"/>
                    <measurement group_id="O2" value="11.8" lower_limit="3.3" upper_limit="34.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="18.4"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" lower_limit="1.0" upper_limit="27.0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bloating</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" lower_limit="1.0" upper_limit="27.0"/>
                    <measurement group_id="O2" value="11.8" lower_limit="3.3" upper_limit="34.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="18.4"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Generalized Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="18.4"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="18.4"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" lower_limit="1.0" upper_limit="27.0"/>
                    <measurement group_id="O2" value="5.9" lower_limit="1.0" upper_limit="27.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal Cramping</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="18.4"/>
                    <measurement group_id="O2" value="5.9" lower_limit="1.0" upper_limit="27.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="18.4"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6" lower_limit="6.2" upper_limit="41.0"/>
                    <measurement group_id="O2" value="11.8" lower_limit="3.3" upper_limit="34.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Loss of appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" lower_limit="1.0" upper_limit="27.0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dizziness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="18.4"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatique</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="18.4"/>
                    <measurement group_id="O2" value="5.9" lower_limit="1.0" upper_limit="27.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urticaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="18.4"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="18.4"/>
                    <measurement group_id="O2" value="11.8" lower_limit="3.3" upper_limit="34.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="18.4"/>
                    <measurement group_id="O2" value="5.9" lower_limit="1.0" upper_limit="27.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Any Adverse Events (AE)</title>
        <time_frame>until Month 6</time_frame>
        <population>Safety Population = all subjects who entered into the study and received at least one vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>VLA1701</title>
            <description>VLA1701 is an investigational oral vaccine against LT-ETEC (Labile Toxin-Enterotoxigenic E coli)&#xD;
The vaccine is administered orally in 2 doses about 1 week apart.&#xD;
VLA1701: VLA1701 is an investigational oral vaccine against LT-ETEC (Labile Toxin-Enterotoxigenic E coli)&#xD;
Challenge Strain: LSN03-016011/A</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>The buffer component of VLA1701 will be used as Placebo.&#xD;
The vaccine is administered orally in 2 doses about 1 week apart.&#xD;
Placebo: buffer component of VLA1701&#xD;
Challenge Strain: LSN03-016011/A</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Any Adverse Events (AE)</title>
          <population>Safety Population = all subjects who entered into the study and received at least one vaccination</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>any unsolicited AE - prior Challenge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6" lower_limit="6.2" upper_limit="41.0"/>
                    <measurement group_id="O2" value="23.5" lower_limit="9.6" upper_limit="47.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any unsolicited AE related - prior Challenge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" lower_limit="3.3" upper_limit="34.3"/>
                    <measurement group_id="O2" value="5.9" lower_limit="1.0" upper_limit="27.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any severe unsolicited AE - prior Challenge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="18.4"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any unsolicited AE lead vacc. withdrawn - prior</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="18.4"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any unsolicite AE leading discontinuation - prior</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="18.4"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any unsolicited AE - entiry study period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.8" lower_limit="36.0" upper_limit="78.4"/>
                    <measurement group_id="O2" value="76.5" lower_limit="52.7" upper_limit="90.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any unsolicited AE related - entire study period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" lower_limit="3.3" upper_limit="34.3"/>
                    <measurement group_id="O2" value="5.9" lower_limit="1.0" upper_limit="27.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any severe unsolicited AE - entire study period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" lower_limit="1.0" upper_limit="27.0"/>
                    <measurement group_id="O2" value="23.5" lower_limit="9.6" upper_limit="47.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>any unsolicited AE leading discontinuation - study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="18.4"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Serious Adverse Events</title>
        <time_frame>until Month 6</time_frame>
        <population>Safety Population = all subjects who entered into the study and received at least one vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>VLA1701</title>
            <description>VLA1701 is an investigational oral vaccine against LT-ETEC (Labile Toxin-Enterotoxigenic E coli)&#xD;
The vaccine is administered orally in 2 doses about 1 week apart.&#xD;
VLA1701: VLA1701 is an investigational oral vaccine against LT-ETEC (Labile Toxin-Enterotoxigenic E coli)&#xD;
Challenge Strain: LSN03-016011/A</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>The buffer component of VLA1701 will be used as Placebo.&#xD;
The vaccine is administered orally in 2 doses about 1 week apart.&#xD;
Placebo: buffer component of VLA1701&#xD;
Challenge Strain: LSN03-016011/A</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Serious Adverse Events</title>
          <population>Safety Population = all subjects who entered into the study and received at least one vaccination</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>prior Challenge</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>entire study period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Any IMP (Investigational Medicinal Product) Related Adverse Events</title>
        <description>unsolicited events</description>
        <time_frame>up to Visit 4 (day of challenge, 23 days post first vaccination)</time_frame>
        <population>Safety Population = all subjects who entered into the study and received at least one vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>VLA1701</title>
            <description>VLA1701 is an investigational oral vaccine against LT-ETEC (Labile Toxin-Enterotoxigenic E coli)&#xD;
The vaccine is administered orally in 2 doses about 1 week apart.&#xD;
VLA1701: VLA1701 is an investigational oral vaccine against LT-ETEC (Labile Toxin-Enterotoxigenic E coli)&#xD;
Challenge Strain: LSN03-016011/A</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>The buffer component of VLA1701 will be used as Placebo.&#xD;
The vaccine is administered orally in 2 doses about 1 week apart.&#xD;
Placebo: buffer component of VLA1701&#xD;
Challenge Strain: LSN03-016011/A</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Any IMP (Investigational Medicinal Product) Related Adverse Events</title>
          <description>unsolicited events</description>
          <population>Safety Population = all subjects who entered into the study and received at least one vaccination</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" lower_limit="3.3" upper_limit="34.3"/>
                    <measurement group_id="O2" value="5.9" lower_limit="1.0" upper_limit="27.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With IMP-related Serious Adverse Events</title>
        <time_frame>up to Visit 4 (day of challenge, 23 days post first vaccination)</time_frame>
        <population>Safety Population = all subjects who entered into the study and received at least one vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>VLA1701</title>
            <description>VLA1701 is an investigational oral vaccine against LT-ETEC (Labile Toxin-Enterotoxigenic E coli)&#xD;
The vaccine is administered orally in 2 doses about 1 week apart.&#xD;
VLA1701: VLA1701 is an investigational oral vaccine against LT-ETEC (Labile Toxin-Enterotoxigenic E coli)&#xD;
Challenge Strain: LSN03-016011/A</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>The buffer component of VLA1701 will be used as Placebo.&#xD;
The vaccine is administered orally in 2 doses about 1 week apart.&#xD;
Placebo: buffer component of VLA1701&#xD;
Challenge Strain: LSN03-016011/A</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With IMP-related Serious Adverse Events</title>
          <population>Safety Population = all subjects who entered into the study and received at least one vaccination</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="18.4"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>until Month 6</time_frame>
      <desc>solicited and unsolicited AEs</desc>
      <group_list>
        <group group_id="E1">
          <title>VLA1701</title>
          <description>VLA1701 is an investigational oral vaccine against LT-ETEC (Labile Toxin-Enterotoxigenic E coli)&#xD;
The vaccine is administered orally in 2 doses about 1 week apart.&#xD;
VLA1701: VLA1701 is an investigational oral vaccine against LT-ETEC (Labile Toxin-Enterotoxigenic E coli)&#xD;
Challenge Strain: LSN03-016011/A</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>The buffer component of VLA1701 will be used as Placebo.&#xD;
The vaccine is administered orally in 2 doses about 1 week apart.&#xD;
Placebo: buffer component of VLA1701&#xD;
Challenge Strain: LSN03-016011/A</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Cerumen impaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Gastrointestinal sounds abnormal</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="17"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Abdominal Tenderness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Suprapubic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Culture stool positive</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Blood Creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Papule</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head Global Medical Affairs</name_or_title>
      <organization>Valneva Austria GmbH</organization>
      <phone>20620 ext 0</phone>
      <email>info@valneva.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

